The genetic basis for inactivation of Wnt pathway in human osteosarcoma
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Osteosarcoma is a highly genetically unstable tumor with poor prognosis. We performed microarray-based comparative genomic hybridization (aCGH), transcriptome sequencing (RNA-seq), and pathway analysis to gain a systemic view of the pathway alterations of osteosarcoma. METHODS: aCGH experiments were carried out on 10 fresh osteosarcoma samples. The output data (Gene Expression Omnibus Series accession number GSE19180) were pooled with published aCGH raw data (GSE9654) to determine recurrent copy number changes. These were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis to identify altered pathways in osteosarcoma. Transcriptome sequencing of six osteosarcomas was performed to detect the expression profile of Wnt signaling pathway genes. Protein expression of WNT1, β-catenin, c-myc, and cyclin D1 in the Wnt pathway was detected by immunohistochemistry (IHC) in an independent group of 46 osteosarcoma samples. RESULTS: KEGG pathway analysis identified frequent deletions of Wnt and other Wnt signaling pathway genes. At the mRNA level, transcriptome sequencing found reduced levels of mRNA expression of Wnt signaling pathway transcripts. While WNT1 protein expression was detected by IHC in 69.6% (32/46) of the osteosarcomas, no β-catenin protein was detected in the nucleus. β-catenin protein expression was, however, detected in the membrane and cytoplasm of 69.6% (32/46) of the osteosarcomas. c-myc protein expression was detected in only 47.8% (22/46) and cyclin D1 protein expression in 52.2% (24/46) of osteosarcoma samples. Kaplan-Meier survival analysis showed that WNT1-negative patients had a trend towards longer disease free survival than WNT1-positive patients. Interestingly, in WNT1-negative patients, those who were also cyclin D1-negative had significantly longer disease free survival than cyclin D1-positive patients. However, there was no significant association between any of the investigated proteins and overall survival of human osteosarcoma patients. CONCLUSIONS: Frequent deletions of Wnt and other Wnt signaling pathway genes suggest that the Wnt signaling pathway is genetically inactivated in human osteosarcoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Genome-Informed Targeted Therapy for Osteosarcoma
Sayles, L. C., Breese, M. R., Koehne, A. L., Leung, S. G., Lee, A. G., Liu, H.-Y., Spillinger, A., Shah, A. T., Tanasa, B., Straessler, K., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1152 · Cited by 452
“The most common genes with an SV were TP53 (29), LRP1B (14), RB1 (8), and FHIT (8).”
BackgroundWnt/β-catenin signaling pathway in carcinogenesis and cancer therapy
Song, P., Gao, Z., Bao, Y., Chen, L., Huang, Y., Liu, Y., Dong, Q., & Wei, X. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01563-4 · Cited by 382
“The inactivation of the Wnt/β-catenin pathway, particularly through the deletion of genes associated with this signaling pathway, such as c-myc and cyclin D1 proteins, also contributes to the development of OS [271].”
BackgroundImmuno-genomic landscape of osteosarcoma
Wu, C.-C., Beird, H. C., Andrew Livingston, J., Advani, S., Mitra, A., Cao, S., Reuben, A., Ingram, D., Wang, W.-L., Ju, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14646-w · Cited by 251
“Characteristic n (%) Median age at diagnosis in years (range) 27 (5-81) Gender Male 29 (60) Female 19 (40) Race White 30 (63) Hispanic 10 (21) Black 5 (10) Asian 3 (6) Disease stage at presentation Localized 37 (77) Metastatic 11 (23) Histologic subtype Osteoblastic 14 (29) Fibroblastic 9 (19) Chondroblastic 6 (13) Ex…”
BackgroundOsteosarcoma mechanobiology and therapeutic targets
Shoaib, Z., Fan, T. M., & Irudayaraj, J. M. K. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15713 · Cited by 233
“In contradiction to a large body of research, there is also evidence of inactivated Wnt/β-catenin signalling in OS cell lines and tumour biopsies (Du et al., 2014).”
BackgroundMartins-Neves, S. R., Paiva-Oliveira, D. I., Fontes-Ribeiro, C., Bovée, J. V. M. G., Cleton-Jansen, A.-M., & Gomes, C. M. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.004 · Cited by 115
Metadata
- Authors
- Du, X., Yang, J., Yang, D., Tian, W., & Zhu, Z.
- Venue
- BMC Cancer
- Published
- 2014-06-18
- Volume
- 14
- Issue
- 1
- Pages
- 450-450
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W1980895192
- Cited by
- 62
- References
- 0
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The genetic basis for inactivation of Wnt pathway in human osteosarcoma. https://app.cochat.ai/papers/10.1186/1471-2407-14-450
- The paper
- Du, X., Yang, J., Yang, D., Tian, W., & Zhu, Z. (2014). The genetic basis for inactivation of Wnt pathway in human osteosarcoma. BMC Cancer. https://doi.org/10.1186/1471-2407-14-450
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.